RZLT Rezolute Inc
Company Analysis
Latest News
🟢 Rezolute is trading 8% up in pre-market after a Craig-Hallum upgrade to Buy
Rezolute is trading at $4.50, up 7.66%, in pre-market on September 29, with a Craig-Hallum Buy upgrade as the clearest fresh potential catalyst. -...
🟢 Rezolute is trading 5% up with no clear catalyst identified
Rezolute is trading 5.26% higher at $4.11, but no confirmed catalyst has been identified for the advance. - No company-specific announcement dated September...
Rezolute reports fourth quarter 2026 net loss of $20.5 million and clinical progress in tumor HI
Rezolute reported a narrowed net loss of $20.5 million for the fourth quarter ended June 30, 2026, as the company focused on late-stage clinical development...
🔴 Rezolute is trading 5.6% down today
Rezolute is trading 5.6% down at $3.73, with no clear company-specific catalyst identified for September 18, 2026. - FDA review of additional ersodetug data...
Rezolute reports Q4 results, highlighting FDA review of ersodetug
Rezolute, Inc. will release its fourth-quarter 2026 earnings after market close on Wednesday, Sept. 16, 2026. Analysts forecast a loss of $0.1479 per share for...
🔴 Rezolute is trading 5.3% down today as broader biotech weakness intensified
Rezolute is trading 5.3% down at $3.93 after broader biotech weakness intensified on September 16, 2026. - The XBI biotech ETF is down 2.11% during regular...
Rezolute Inc Q2 2026 Earnings Preview: What Analysts Expect on September 16, 2026
Rezolute Inc is expected to report a consensus EPS loss of $0.14 on zero revenue for the quarter ending June 30, 2026, with its current stock price of $4.22...
🟢 Rezolute is trading 6% up today after the FDA continued reviewing failed Phase 3 data
Rezolute is trading at $4.29, up +5.67%, rebounding after announcing on September 9, 2026 that the FDA continues reviewing data from its failed Phase 3 sunRIZE...
Rezolute's Failed Trial Still Has the FDA Talking — Is That Enough to Justify a $440 Million Bet?
Shares shifted as Rezolute (RZLT) jumped +10.84% to $4.50 on September 10, defying a down market after disclosing that the FDA's review of its failed Phase 3...
🟢 Rezolute is trading 11% up today in pre-market as FDA continues reviewing Phase 3 sunRIZE data
Rezolute is trading 10.84% up now at $4.50 in pre-market after its September 9, 2026 update said the FDA’s review of additional Phase 3 sunRIZE data remains...
🟢 Rezolute is trading 5.77% up today in pre-market as FDA continues reviewing Phase 3 sunRIZE data
Rezolute is trading at $4.29, up 5.77% in pre-market after its September 9, 2026 update that the FDA continues reviewing Phase 3 sunRIZE data. - The study...
🔴 Rezolute is trading 5% down today after FDA review has no timeline
Rezolute is trading 5.11% down at $4.17 after announcing on September 9, 2026, that the FDA is still reviewing Phase 3 sunRIZE data without a specific timeline...
🔴 Rezolute is trading 5% down today amid biotech and broader market weakness
Rezolute is trading 5.01% down now at $4.46, alongside a 4.24% drop in biotechnology stocks and losses across major U.S. indexes, suggesting sector and broader...
🟢 Rezolute is trading 5.6% up in after-hours trading despite no identified catalyst
Rezolute is trading at $4.88, up 5.63% after an unexplained after-hours rebound following its August 28 regular-session decline. - Shares fell 7.23% during...
🔴 Rezolute is trading 5% down today amid biotech-sector selloff
Rezolute is trading 5% down at $4.73 after a broad biotech-sector selloff; XBI fell 2.31% during regular trading. - The decline appears sector-driven....
🟢 Rezolute is trading 7.14% up in pre-market after Nvidia beat estimates and raised outlook
Rezolute is trading 7.14% up in pre-market at $5.40, mainly amid broader risk-on sentiment after Nvidia beat quarterly estimates and raised its outlook. - No...
🟢 Rezolute is trading 7.78% up in pre-market amid broader overnight risk-on sentiment
Rezolute is trading 7.78% up in pre-market at $5.40, apparently linked to broader overnight risk-on sentiment rather than a confirmed company-specific...
🟢 Rezolute is trading 5.59% up in pre-market amid broader risk-on sentiment
Rezolute is trading at $5.29, up 5.59%, possibly supported by broader risk-on sentiment. - Nasdaq futures are up 0.65%, and technology shares are...
🟢 Rezolute is trading 13% up today
Rezolute is trading 12.66% up at $5.25, but no clear company-specific catalyst was identified for August 21, 2026. - The latest identifiable material update...
🟢 Rezolute is trading 9.98% up today — catalyst remains unclear
Rezolute is trading 9.98% up at $5.12, but no clear company-specific catalyst was identified for August 21, 2026. - The latest identifiable update remains...